SAN DIEGO--(BUSINESS WIRE)--Orexigen™ Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders, including obesity, today announced the 48-week results of the Phase IIb clinical trial of Empatic™, one of its two obesity drug candidates. Weight loss through 48 weeks for the highest Empatic dosage arm, in the intent-to-treat (ITT)--double blind extension and completer groups (see discussion below), was 14.0% and 15.1%, respectively.
